APOE and Alzheimer disease: In recent data obtained by analyzing in two electronic health record databases, a large cohort of patients affected by different neuro-pathologies clearly showed that treatment with bumetanide, a selective antagonist of the chloride importer NKCC1, prevents the development of APOE4-related forms of AD in individuals over the age of 65 years [161].